• 1.

    Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity—What the FK? Adv Chronic Kidney Dis 2020; 27:5666. doi: 10.1053/j.ackd.2019.08.006

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Vincenti F, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698. doi: 10.1056/NEJMx160003

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Adams AB, et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 2017; 17:29222936. doi: 10.1111/ajt.14353

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Cicora F, et al. Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: A proof-of-concept study. Transpl Immunol 2015; 32:3539. doi: 10.1016/j.trim.2014.10.002

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Kumar D, et al. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne) 2017; 4:60. doi: 10.3389/fmed.2017.00060

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Ferguson R, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:6676. doi: 10.1111/j.1600-6143.2010.03338.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Radbruch A, et al. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6:741750. doi: 10.1038/nri1886

  • 8.

    Ajaz B, et al. Plasma cell CD20 expression: Primary aberrant expression or receptor up-regulation. Leuk Lymphoma 2014; 55:444446. doi: 10.3109/10428194.2013.802782

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Lee J, et al. The effect of bortezomib on antibody-mediated rejection after kidney transplantation. Yonsei Med J 2015; 56:16381642. doi: 10.3349/ymj.2015.56.6.1638

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Woodle ES, et al. Plasma cell targeting to prevent antibody-mediated rejection. Am J Transplant 2020; 20:3341. doi: 10.1111/ajt.15889

Novel Therapeutics in Kidney Transplantation Belatacept, Bortezomib, Battlestar Galactica

  • 1 Samira S. Farouk, MD, MSCR, FASN, is affiliated with the Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Restricted access
Save